What is William Blair’s Forecast for MDxHealth Q1 Earnings?

MDxHealth SA (NASDAQ:MDXH) – William Blair issued their Q1 2026 earnings per share (EPS) estimates for MDxHealth in a report released on Wednesday, February 26th. William Blair analyst A. Brackmann anticipates that the company will earn ($0.13) per share for the quarter. The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.05) EPS.

Separately, Piper Sandler reduced their price objective on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th.

MDxHealth Stock Down 2.2 %

MDXH stock opened at $1.82 on Friday. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The stock has a market capitalization of $86.06 million, a P/E ratio of -1.20 and a beta of 1.34. The business has a 50-day moving average of $2.00 and a 200-day moving average of $2.19. MDxHealth has a fifty-two week low of $1.55 and a fifty-two week high of $3.85.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. The company had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MDXH. Perkins Capital Management Inc. boosted its position in MDxHealth by 70.7% during the third quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after purchasing an additional 309,500 shares during the last quarter. MVM Partners LLC lifted its position in shares of MDxHealth by 3.3% in the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock valued at $9,706,000 after buying an additional 150,000 shares during the last quarter. OneDigital Investment Advisors LLC lifted its position in shares of MDxHealth by 15.3% in the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock valued at $120,000 after buying an additional 7,656 shares during the last quarter. Maven Securities LTD bought a new position in shares of MDxHealth during the third quarter worth approximately $208,000. Finally, Oppenheimer & Co. Inc. increased its stake in shares of MDxHealth by 100.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after purchasing an additional 10,000 shares during the period.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.